Sunday, May 29, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Marine resources could be promising drug candidates against SARS-CoV-2 Omicron

by Medical Finance
in Coronavirus
Study: A Short Overview: Marine Resources as Potential Interventions for the Omicron SARS-CoV-2 Variant. Image Credit: HedvikaMichnova / Shutterstock
9
SHARES
100
VIEWS
Share on FacebookShare on Twitter

A recent review paper, published in the MDPI’s specialized journal COVID, highlights key features of the Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – and examines the potential and roadblocks in using renewable marine resources in the fight against the coronavirus disease 2019 (COVID-19).

Study: A Short Overview: Marine Resources as Potential Interventions for the Omicron SARS-CoV-2 Variant. Image Credit: HedvikaMichnova / ShutterstockStudy: A Short Overview: Marine Resources as Potential Interventions for the Omicron SARS-CoV-2 Variant. Image Credit: HedvikaMichnova / Shutterstock

Of all the SARS-CoV-2 variants, the most recent one, known as Omicron, harbors the most significant number of mutations that give the viral particles an improved ability to infect and transmit between hosts, as well as to avoid immune protection (either following the infection or after vaccination).

Akin to other strains, the Omicron SARS-CoV-2 variant gains access to the human cells by using the receptor-binding domain (RBD) of the spike glycoprotein to connect with the cell receptor angiotensin-converting enzyme 2 (ACE2). This is the pathway that holds the most promise for drug development.

But new therapeutics against COVID-19 are just starting to enter the market, with many still in the preclinical development phases. Marine resources have significant activity against cancerous cells, viruses and bacteria; therefore, their ability to halt or treat Omicron viral infection is a promising research avenue to pursue.

More specifically, marine resources that can be isolated from invertebrates and cultivated under farming conditions (such as sponges) are highly advantageous over synthetic compounds as they are environmentally friendly, metabolically compatible and contain little (or no) toxins.

In this short (but comprehensive) overview, Dr. Sarah Geahchan, Dr. Herman Ehrlich and Dr. Azizur Rahman (all of them affiliated with the University of Toronto in Canada) have summarized key studies and reports exploring the SARS-CoV-2 Omicron variant in the context of marine resources.

A comparison of few key missense mutations in the spike protein of previous SARS-CoV-2 variants and the omicron variant. As seen in the image on the left, previous variants (i.e., delta variant) had few mutations that favored viral infection. Seen on the right, omicron has more mutations, many of which function to increase binding affinity to host ACE-2 receptor and potentially increase infectivity ability as well as transmissibility of viral particles. Some mutations such as T478K overlap with previous variants, and some (i.e., E484A) are unique to omicron. (Created with BioRender.com (accessed on 19 December 2021)).A comparison of few key missense mutations in the spike protein of previous SARS-CoV-2 variants and the omicron variant. As seen in the image on the left, previous variants (i.e., delta variant) had few mutations that favored viral infection. Seen on the right, omicron has more mutations, many of which function to increase binding affinity to host ACE-2 receptor and potentially increase infectivity ability as well as transmissibility of viral particles. Some mutations such as T478K overlap with previous variants, and some (i.e., E484A) are unique to omicron. (Created with BioRender.com (accessed on 19 December 2021)).

Marine compounds and SARS-CoV-2

The propensity of marine compounds to inhibit and interfere with several stages of the viral life cycle makes them more advantageous when compared to current drugs (such as remdesivir). Targeting conserved enzymes like RNA-dependent RNA polymerase of the virus (RdRp) and main protease and conserved regions on the RBD are promising venues for tackling emerging viral variants.

One notable example are compounds such as inorganic polyphosphate and natural bromotyrosines that have been shown to contain multiple mechanisms of action against SARS-CoV-2 and other viruses. In addition, metabolites produced by marine organisms may prevent viral entry, viral replication and protein synthesis, thus completely halting the viral life cycle.

Furthermore, lambda-carrageenan is a polysaccharide found in red algae that can inhibit influenza virus and SARS-CoV-2 viral replication in a dose-dependent fashion. Studies have shown how lambda-carrageenan is able to halt viral entry and viral protein synthesis, primarily by blocking the transcription and translation of proteins. 

Overview of marine compounds interfering with the SARS-CoV-2 viral life cycle. Image depicts several marine substances that can inhibit various steps of the life cycle which may be relevant to treatment.Overview of marine compounds interfering with the SARS-CoV-2 viral life cycle. Image depicts several marine substances that can inhibit various steps of the life cycle which may be relevant to treatment.

And then, there is a recent study that pinpointed natural bioactive compounds in a plethora of marine seaweed species as potent inhibitors of the Omicron SARS-CoV-2 variant. Molecular docking analysis revealed two compounds – phloretin and caffeic acid hexoside – that have the power to inhibit important residues critical for the interaction of the virus with the cell receptor.

Taking everything into account, it is relatively clear that various seaweed compounds and metabolites found in other marine organisms may be rather effective against the infection with the Omicron variant, pending future experimental studies for steadfast evidence on this.

The RBD of SARS-CoV-2 delta variant and omicron variant. Image depicts a comparison of the mutations present in the delta variant (A) and omicron variant (B), with a shared mutation at the 478-residue position.The RBD of SARS-CoV-2 delta variant and omicron variant. Image depicts a comparison of the mutations present in the delta variant (A) and omicron variant (B), with a shared mutation at the 478-residue position.

Challenges ahead

Of course, the potential development of drugs from marine resources is not without several notable challenges. First, even though the small scale is environmentally friendly, as we have mentioned before, large-scale production and continuous supply of resources may have an inverse effect and actually harm the ecosystem.

Moreover, most research studies that used marine resources for COVID-19 and other viral agents have been conducted in vitro, but we lack data on their in vivo efficacy and safety studies, let alone clinical trials that would confirm their actual antiviral activity.

And even if these studies start now, they are very time-consuming, which means the benefits of applying these drugs to current SARS-CoV-2 variants are rather limited. Still, that should not prevent the development process, considering the potential emergence of novel variants (or even novel coronaviruses).

Implications and future steps

Even though a substantial amount of knowledge has been accumulated on how the SARS-CoV-2 Omicron variant differs from other variants, many question marks still have to be answered before we can introduce new compounds based on marine resources. There is also an additional concern regarding the potential emergence of other viral strains as well.

“The development of natural compounds from marine resources proves advantageous against the evolving SARS-CoV-2 variants due to their multifaceted mechanisms of action and their promising in vitro results”, say study authors in this paper published in the journal COVID.

“Developing compounds that target RdRp and main protease of the virus, as well as conserved residues in the RBD important for binding the ACE-2 receptor is where the focus of drug development should be”, they additionally emphasize.

In any case, it is clear that booster vaccine doses are rather beneficial in our fight against the SARS-CoV-2 Omicron variant, but several studies have shown that the evolving virus may escape the host immune response. This consequently opens the door for using different compounds found in marine life to our advantage.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Selection analysis identifies unusual clustered mutational changes in Omicron lineage BA.1 that likely impact Spike function. Image Credit: Naeblys/Shutterstock

Impact of clustered mutations in SARS-CoV-2 Omicron spike function

by Medical Finance
May 29, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers explored the characteristics of severe acute respiratory syndrome coronavirus...

Study: “Never let a good crisis go to waste”: Positives from disrupted maternity care in Australia during COVID-19. Image Credit: Prostock-studio/Shutterstock

Positive effects of altered maternal care during COVID-19 in Australia

by Medical Finance
May 29, 2022
0

In a recent study published in Midwifery, researchers reported on the positive outcomes of the coronavirus disease 2019 (COVID-19) pandemic...

Study: Omicron infection enhances Delta antibody immunity in vaccinated persons. Image Credit: NIAID

SARS-CoV-2 Omicron infection boosts Delta immunity in those who have been vaccinated

by Medical Finance
May 29, 2022
0

The severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) Omicron variant that was first identified in South Africa and Botswana in...

Durable neutralizing response against Omicron after heterologous vaccine boosting

Durable neutralizing response against Omicron after heterologous vaccine boosting

by Medical Finance
May 29, 2022
0

The currently dominant circulating Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) consists of a number of...

Study: Abnormal global alternative RNA splicing in COVID-19 patients. Image Credit: NIAID

RNA splicing abnormalities in COVID-19 patients

by Medical Finance
May 28, 2022
0

The ongoing coronavirus disease 2019 (COVID-19) pandemic has not only resulted in global public health crises but has also created...

Booster vaccine provides similar protection in SARS-CoV-2 naive and convalescent individuals

Booster vaccine provides similar protection in SARS-CoV-2 naive and convalescent individuals

by Medical Finance
May 28, 2022
0

The benefit of coronavirus disease 2019 (COVID-19) vaccination among people with a history of severe acute respiratory syndrome coronavirus 2...

Next Post
Study: Selection analysis identifies unusual clustered mutational changes in Omicron lineage BA.1 that likely impact Spike function. Image Credit: Naeblys/Shutterstock

Impact of clustered mutations in SARS-CoV-2 Omicron spike function

AI-driven solution predicts RNA and DNA binding sites to accelerate rational drug discovery

Applying a form of AI to sift through large amounts of biological data

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Accident Injury Information Report Health Rawpixel.com ac5524c1031e4229bc369a9a2a504d1c 620x480
    Record ACA enrollment puts pressure on Congress
  • Study: Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals, Image Credit: karegg / Shutterstock
    Comparing SARS-CoV-2 Delta and Omicron waves in Germany
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply